DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to ...

Perrigo Company plc (PRGO) is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results und ...

Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple Expected Net Proceeds to be Redeployed for Debt Repayment Expected Impact From this Proposed Divestment was In ...

DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

Core Viewpoint - Perrigo has a strong history of increasing dividends for 20 consecutive years and is positioned to achieve Dividend Champion status, supported by several catalysts in 2024 that could enhance share price and dividend growth [2][26]. Company Overview - Perrigo is a leading provider of over-the-counter medications and therapeutic products, holding a 49% market share in self-care products in the USA, Canada, Europe, and Australia [3][5]. - The healthcare sector is expected to grow long-term due to aging populations and the increasing demand for self-care products [5]. Recent Challenges and Recovery - Perrigo faced difficulties following a proposed acquisition by Mylan, which merged with Upjohn to form Viatris in 2020, impacting its performance over the past decade [5][6]. - The company had to shut down a Wisconsin infant formula plant due to FDA findings, leading to a 25% decline in share price. However, the plant has resumed operations, and revenue from it is expected to contribute positively in 2024 and 2025 [7][9]. Catalysts for Growth - **Manufacturing and Supply Chain Optimization**: The new CEO aims to unlock $150-$200 million in adjusted operating income by 2025 through initiatives like reducing SKU complexity and improving business planning [10][11][14]. - **Good-Better-Best Branding Strategy**: Perrigo plans to introduce a mid-tier product line in the USA, which could improve gross margins by 10-12 percentage points and tap into a growing market segment [19][20]. - **Launch of Opill**: The introduction of Opill, an OTC oral contraceptive, is expected to capture a significant market share, with strong retail support and potential insurance coverage enhancing its adoption [20][21]. - **Upcoming Investor Day**: The company plans to host an investor day to outline strategies for increasing shareholder returns, focusing on dividend growth, deleveraging, and reinvestment in higher-margin product categories [22][25]. Financial Performance and Outlook - Perrigo's gross margin has improved from 36.5% in 2021 to a target of over 40% in the long term, driven by operational efficiencies and pricing strategies [17][18]. - The company is on track to reduce its net leverage ratio to below 3.0X adjusted EBITDA by the end of 2025, contributing to earnings growth [23][25]. Market Position and Future Prospects - The self-care market is projected to grow at a 4% CAGR, with Perrigo positioned to benefit from this trend through its strategic initiatives and product offerings [32][33]. - The company is recognized for its consistent dividend payments, with a current yield of 3.5%, which is attractive compared to other investment options [26][39].

Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-order from select retailers beginning this week   To maximize the impact and accessibility of Opill®, Perrigo has sought to ensure both the affordability and availability of Opill® on shelves across the country and online DUBLIN and GRAND RAPIDS, Mich., March 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRG ...

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13th at 4:00 PM EST.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a ...

Perrigo Company plc (PRGO) reported adjusted earnings of 86 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of 83 cents. Earnings were up 14.7% year over year. The upside can be attributed to lower operating expenses incurred by the company during the quarter.Net sales increased 0.1% year over year to $1.16 billion, missing the Zacks Consensus Estimate of $1.19 billion. The upside was driven by growth stemming from the acquisition of the U.S. & Canadian Good Start infant ...

Financial Data and Key Metrics Changes - Net sales in fiscal 2023 grew nearly 5%, driven by international and core US OTC businesses, with organic net sales increasing 2% [7][29] - Gross margin expanded 260 basis points to 38.8%, and operating margin expanded 130 basis points to 12.3% for the full year [7][30] - Full-year EPS was $2.58, an increase of 25% compared to the prior year, with strong cash flow conversion of 115% [7][31] Business Line Data and Key Metrics Changes - Significant growth was realized in skincare, nutrition, and women's health categories, partially fueled by HRA and Gateway acquisitions [8] - Healthy Lifestyle contributed strong growth, particularly in US smoking cessation products, while cough cold sales in the US grew mid-single digits [8][9] - The infant formula business faced challenges due to evolving regulatory guidelines, impacting overall performance [6][11] Market Data and Key Metrics Changes - Store brand dollar share of US OTC increased by 70 basis points, indicating a shift towards value offerings among consumers [9] - The US OTC business is performing well amid a normalizing consumer environment, with store brands gaining market share from national brands [5][6] Company Strategy and Development Direction - The company is focused on augmenting and strengthening its infant formula business while executing Project Energize to enhance operational efficiency [10][15] - The launch of Opill is seen as a key pillar for growth in women's healthcare, with plans for a comprehensive marketing strategy [20][23] - The company aims to centralize capital allocation decisions and streamline operations to enhance decision-making and simplify commercial operations [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in stabilizing the infant formula business despite current challenges, with expectations for recovery in the second half of 2024 [14][22] - The company anticipates mid-teens EPS growth in 2024, excluding the impact of the infant formula business, which is expected to be flat compared to 2023 [21][33] - Management emphasized the importance of executing remediation plans and enhancing brand-building capabilities to drive future growth [39][41] Other Important Information - The company reported a GAAP net loss of $4 million for 2023, with adjusted net income of $352 million [27] - Cash on the balance sheet increased to $751 million, with expectations for healthy cash flow conversion in 2024 [34][35] - The company plans to pay down $400 million in debt and increase capital investments in the infant formula business [35][36] Q&A Session Summary Question: Expectations for infant formula top line recovery - Management expects the first quarter to be the worst for infant formula, with gradual improvement anticipated throughout the year [46][47] Question: Long-term profitability of the infant formula business - The goal is to return to historical profit levels, with an ambition to achieve around $140 million in operating income [48][49] Question: Rollout plans for Opill - Opill is set for a nationwide rollout with strong retail and online activation plans, expected to generate significant initial revenue [50][51] Question: Confidence in resolving nutritional issues - Management expressed confidence in the remediation efforts, citing previous successful interventions in similar regulated industries [55][56] Question: Competitive landscape and share loss concerns - Management is working closely with retailers to minimize disruption and retain partnerships, emphasizing the importance of quality assurance [59][60] Question: 2025 targets and growth perspectives - Management plans to provide clearer growth perspectives during the Investor Day in the fall, focusing on executing current priorities [61][62]

Perrigo (PRGO) reported $1.16 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.2%. EPS of $0.86 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.19 billion, representing a surprise of -2.51%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...